- Home
- RPRX vs HOLX Comparison
RPRX vs HOLX Comparison
Compare RPRX & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | HOLX |
|---|---|---|
| Founded | 1996 | 1985 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 16.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RPRX | HOLX |
|---|---|---|
| Price | $45.16 | $75.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 13 |
| Target Price | $47.75 | ★ $77.89 |
| AVG Volume (30 Days) | ★ 4.2M | 2.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.10 | $6.01 |
| Revenue Next Year | $5.02 | $5.29 |
| P/E Ratio | ★ $25.25 | $31.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.66 | $51.90 |
| 52 Week High | $46.14 | $75.36 |
Technical Indicators
Market Signals| Indicator | RPRX | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 73.30 | 59.91 |
| Support Level | $42.50 | $74.89 |
| Resistance Level | $46.14 | $75.29 |
| Average True Range (ATR) | 1.00 | 0.24 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 82.91 | 91.14 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.